Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (321-330 of 337) with videos related to

Pageof 34
Sort By:
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Science Translational Medicine|April 19, 2023
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trialDavid Benkeser, David C Montefiori, Adrian B McDermott, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention TrialsCarolyn Williamson, Lyle Curry, Nonhlanhla N Mkhize, et al.
Nature Communications|January 17, 2025
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boostBo Zhang, Youyi Fong, Lauren Dang, et al.
Viruses|October 28, 2023
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 TrialYing Huang, Nima S Hejazi, Bryan Blette, et al.
Nature Communications|March 12, 2024
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig A Magaret, Li Li, Allan C deCamp, et al.
Journal of Virology|May 16, 2014
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trialAndrew J Gartland, Sue Li, John McNevin, et al.
Ebiomedicine|August 24, 2025
Corrigendum to 'Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study'. EBioMedicine 2024;108: 105320Avi Kenny, Janine van Duijn, One Dintwe, et al.
Ebiomedicine|September 5, 2024
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control studyAvi Kenny, Janine van Duijn, One Dintwe, et al.
Pageof 34

Showing results (321-330 of 337) with videos related to

Sort By:
Pageof 34
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Science Translational Medicine|April 19, 2023
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trialDavid Benkeser, David C Montefiori, Adrian B McDermott, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention TrialsCarolyn Williamson, Lyle Curry, Nonhlanhla N Mkhize, et al.
Nature Communications|January 17, 2025
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boostBo Zhang, Youyi Fong, Lauren Dang, et al.
Viruses|October 28, 2023
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 TrialYing Huang, Nima S Hejazi, Bryan Blette, et al.
Nature Communications|March 12, 2024
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig A Magaret, Li Li, Allan C deCamp, et al.
Journal of Virology|May 16, 2014
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trialAndrew J Gartland, Sue Li, John McNevin, et al.
Ebiomedicine|August 24, 2025
Corrigendum to 'Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study'. EBioMedicine 2024;108: 105320Avi Kenny, Janine van Duijn, One Dintwe, et al.
Ebiomedicine|September 5, 2024
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control studyAvi Kenny, Janine van Duijn, One Dintwe, et al.
Pageof 34